论文部分内容阅读
目的比较伊立替康+铂类(IP)方案与EP方案治疗小细胞肺癌(small cell lung cancer,SCLC)的疗效及生存期。方法 73例小细胞肺癌患者随机分为两组,以顺铂或奈达铂为基础,分别使用足叶乙甙或伊立替康进行化疗。结果 IP组28例,有效率58.3%;EP组45例,有效率30%(P=0.025),但比较两组生存时间差异有统计学意义。结论 EP和IP方案均是治疗SCLC的有效方案,与EP方案相比,IP方案疗效更好,且血液学毒性较低。
Objective To compare the efficacy and survival of irinotecan + platinum (IP) and EP regimen in the treatment of small cell lung cancer (SCLC). Methods Totally 73 patients with small cell lung cancer were randomly divided into two groups. The patients were treated with cisplatin or nedaplatin, respectively, with etoposide or irinotecan. Results In the IP group, the effective rate was 58.3% in 28 cases and in 45 cases in EP group, the effective rate was 30% (P = 0.025). However, the difference in survival time between the two groups was statistically significant. Conclusion Both EP and IP regimens are effective regimens for the treatment of SCLC. Compared with EP regimen, IP regimen is more effective and less toxic to hematology.